# A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

> **NCT06980207** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Luye Pharma Group Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
- Hallucinations and Delusions Associated With Parkinson Disease Psychosis
- Negative Symptoms of Schizophrenia

## Interventions

- **DRUG:** LY03017
- **DRUG:** LY03017-Placebo

## Key facts

- **NCT ID:** NCT06980207
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06980207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06980207, "A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06980207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*